Back to News
Market Impact: 0.15
IDEAYA Reports Improvements In OS & Tumor Shrinkage For Darovasertib In Uveal Melanoma
Source: Nasdaq
Healthcare & Biotech
IDEAYA Biosciences released updated clinical data from three trials evaluating darovasertib for metastatic and primary uveal melanoma. The article excerpt provides no trial results, numerical data, or other details on the findings.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
IDYA0.50
More News
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Why is Intuitive Surgical stock sliding today?
- Disc Medicine prices $450 million stock offering at $75/share
- Alpha Teknova stock tumbles on public offering announcement